Related Experiment Video
Updated: May 20, 2026
09:16
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis
Ching-Shya Yong1, Chih-Ming Ou Yang, Yenn-Hwei Chou
1Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, No.95 Wen Chang Road, Shih Lin District, Taipei City 11120, Taiwan.
BMC Gastroenterology
|July 31, 2012
Summary
This study found that neither CD44 nor CD24 expression, individually or combined, is associated with gastric cancer recurrence. Further research is needed to identify molecular signatures predicting recurrence in gastric carcinoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastric cancer is a leading cause of cancer mortality with a high recurrence rate.
- The molecular signatures driving gastric cancer recurrence remain largely unidentified.
- Understanding recurrence predictors is crucial for improving patient prognosis.
Purpose of the Study:
- To investigate the correlation between CD44 and CD24 expression levels and the recurrence of gastric cancer.
- To determine if CD44/CD24 expression can serve as a prognostic biomarker for gastric carcinoma.
- To identify potential molecular targets for predicting gastric cancer relapse.
Main Methods:
- Retrospective review of hospital records for 500 gastric cancer patients undergoing curative resection.
- Selection of 20 patients with recurrence (study group) and 20 without recurrence (control group).
- Immunohistochemical analysis of CD44 and CD24 expression in tumor tissues to assess correlation with recurrence rates.
Main Results:
- The study group with recurrence exhibited higher TNM stage and significantly more lymph node metastasis compared to the control group.
- Univariate and multivariate analyses showed no statistically significant association between CD44 expression and gastric cancer recurrence.
- Similarly, CD24 expression, individually or in combination with CD44, was not found to be significantly associated with the risk of gastric carcinoma recurrence.
Conclusions:
- Individual expression of CD44 or CD24 does not predict recurrence in gastric cancer patients.
- Combined CD44/CD24 expression is not a significant factor for predicting gastric carcinoma recurrence.
- Novel biomarkers are required to identify patients at high risk for gastric cancer relapse.